Critical appraisal of biosimilar filgrastim (Nivestim™) for febrile and chemotherapy-induced neutropenia

Overview of attention for article published in Biosimilars, August 2012

Altmetric Badge

Mentioned by

facebook: 1 Facebook page

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 9 Mendeley

Summary Facebook Dimensions citations

So far, Dimensions has found 9 publications that cite this research output.

9

The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.

Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study

Article in Journal of Medical Economics (March 2023)

The Impact of Biosimilars in Supportive Care in Cancer

Article in European Oncology & Haematology (January 2018)

Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation

Article in Transfusion (July 2015)